MacGilchrist A J, Deighton N M, Hamilton C A, Reid J L
University Department of Materia Medica, Stobhill Hospital, Glasgow, Scotland.
Br J Clin Pharmacol. 1990 Oct;30(4):644-7. doi: 10.1111/j.1365-2125.1990.tb03828.x.
Radioligand binding studies were performed on 10 patients with cirrhosis and 10 healthy subjects. Bmax and KD of platelet alpha 2-adrenoceptors, studied using [3H]-yohimbine, were similar in both groups (Bmax 24.9 vs 22.1 fmol/10(9) platelets, P = 0.47; KD 4.6 vs 5.5 nmol 1-1, P = 0.56). Bmax and KD of lymphocyte beta 2-adrenoceptors, studied using [125I]-iodocyanopindolol, were also similar in both groups (Bmax 24.0 vs 27.2 fmol mg-1 protein, P = 0.55; KD 49.6 vs 55.3 pmol 1-1, P = 0.65). In this model there is no evidence of adrenoceptor down-regulation in cirrhosis despite the increased sympathetic activity in this condition.
对10例肝硬化患者和10名健康受试者进行了放射性配体结合研究。使用[3H] -育亨宾研究的血小板α2 -肾上腺素能受体的Bmax和KD在两组中相似（Bmax分别为24.9和22.1 fmol/10(9)血小板，P = 0.47；KD分别为4.6和5.5 nmol 1-1，P = 0.56）。使用[125I] -碘氰吲哚洛尔研究的淋巴细胞β2 -肾上腺素能受体的Bmax和KD在两组中也相似（Bmax分别为24.0和27.2 fmol mg-1蛋白质，P = 0.55；KD分别为49.6和55.3 pmol 1-1，P = 0.65）。在该模型中，尽管肝硬化患者交感神经活动增加，但没有证据表明存在肾上腺素能受体下调。
